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Background
Myocardial fibrosis is a hallmark of hypertrophic cardiomyopathy (HCM) and may contribute to arrhythmias and heart failure. Sarcomere mutations appear to induce profibrotic changes before left ventricular hypertrophy (LVH) develops. Measuring T1 relaxation times with contrast cardiac magnetic resonance (CMR) allows robust quantification of the cardiac extracellular volume (ECV) and noninvasive assessment of diffuse myocardial fibrosis.
Methods
A genotyped HCM population underwent contrast CMR with measurement of T1. Subjects included sarcomere mutation carriers with LVH (G+/LVH+, n = 37) and without LVH (G+/LVH-, n = 30); HCM patients without mutations (sarcomere-negative HCM, n = 11); and mutation-negative healthy controls (n = 10). Concurrent echocardiography and serum biomarkers of collagen synthesis, hemodynamic stress, and myocardial injury were available in a subset.
Results
Late gadolinium enhancement (LGE) was present in >60% of overt HCM patients but absent from G+/LVHsubjects. Compared to controls, ECV was increased in patients with overt HCM, as well as G+/LVH-mutation ECV was correlated with NT-proBNP levels (r=0.61, P<0.001) and global E' velocity (r=-0.48, P<0.001). ECV and LGE were higher in sarcomeric HCM than sarcomere-negative HCM.
Conclusions
Myocardial ECV is increased not only in sarcomere mutation carriers with overt HCM, but also those with normal LV wall thickness. These data provide further evidence that fibrotic remodeling is triggered early in disease pathogenesis. Assessing ECV may help characterize the development of HCM-induced myocardial fibrosis, ultimately supporting novel strategies to modify disease by targeting interstitial fibrosis. Submit your manuscript at www.biomedcentral.com/submit Figure 1 ECV is significantly increased in HCM sarcomere mutation carriers both with and without LVH Compared to normal controls, ECV was 25% in G+/LVH-subjects and 42% higher in G+/LVH+ HCM patients (p<0.001 for all comparisons to controls). ECV was further increased by 13% in overt HCM compared to G+/LVHsubjects (p=0.0003).
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